6550 Polaris Pharmaceuticals-KY

Release Date: July 15, 2026 Statement Date: July 14, 2026 Statement Time: 17:55:56 Company Code: 6550 Company Name: Polaris Pharmaceuticals-KY Subject: Announcement that the Company has received a notice from the Taiwan Stock Exchange Corporation suspending the effectiveness of its capital reduction filing.

Applicable Clause: Item 51 Factual Date: July 14, 2026

Details: 1. Factual Date: 7/14/115 (July 14, 2026) 2. Company Name: Polaris Pharmaceuticals Group Corporation 3. Relationship to Company (enter '本公司' or 'Subsidiary'):本公司 (Our Company) 4. Cross-shareholding Ratio: Not applicable 5. Reason for Occurrence: The Company filed an application with the Taiwan Stock Exchange Corporation on June 26, 2026, to reduce its capital by NT$4,299,463,440. The Taiwan Stock Exchange Corporation has notified the Company that certain items in the filing documents require additional explanation. Accordingly, under the provisions of the 'Regulations Governing the Offering and Issuance of Securities by Foreign Issuers', the effectiveness of this capital reduction filing is suspended starting July 14, 2026, and the Company has been instructed to make the necessary corrections as required. 6. Response Measures: The Company will promptly complete the required supplementary explanations and document corrections in accordance with the regulatory authority's notice, and will reapply within the statutory period to resume the capital reduction filing process. 7. Other Matters to be Disclosed (If the subject of the event or resolution is a publicly listed company or above, this material information also qualifies under Article 7, Paragraph 9, Item 9 of the Enforcement Rules of the Securities and Exchange Act as a matter having a material impact on shareholders' rights or securities prices): The suspension of the filing's effectiveness pertains solely to procedural corrections and has no material impact on the Company's existing operations or financial condition.